Lexeo Therapeutics is projected to report a Q3 2026 net loss of $0.33 per share on zero revenue, while the stock currently trades at $3.32 against an average analyst price target of $25.11. Investors are primarily focused on the interim Phase 1/2 clinical data from the HEROIC-PKP2 trial for LX2020, seeking evidence of sustained arrhythmia reduction in patients with arrhythmogenic cardiomyopathy.
The company has maintained momentum with the recent initiation of its SUNRISE-FA 2 pivotal study and the receipt of FDA RMAT designation for LX2020. Management’s update on the cash runway, currently estimated at approximately $220 million, will be crucial for assessing the firm's ability to fund its cardiovascular and neurological gene therapy pipeline through 2027.